Tradename | Company | Number | Date | Products |
---|---|---|---|---|
SYNTHROID | AbbVie | N-021402 RX | 2002-07-24 | 12 products, RLD |
THYRO-TABS | Alvogen | N-021116 RX | 2002-10-24 | 12 products, RLD |
THYQUIDITY | Azurity | N-214047 RX | 2020-11-30 | 1 products, RLD, RS |
LEVO-T | Cediprof | N-021342 RX | 2002-03-01 | 12 products |
LEVOTHYROXINE SODIUM | Fresenius Kabi | N-202231 RX | 2011-06-24 | 3 products, RLD, RS |
LEVOTHYROXINE SODIUM | Fresenius Kabi | N-210632 RX | 2019-04-11 | 3 products, RLD, RS |
LEVOLET | Genus Lifesciences | N-021137 RX | 2003-06-06 | 12 products |
LEVOTHYROXINE SODIUM | Hikma Pharmaceuticals | N-214253 RX | 2021-05-17 | 1 products, RLD, RS |
TIROSINT | IBSA Group | N-021924 RX | 2006-10-13 | 15 products, RLD |
TIROSINT-SOL | IBSA Group | N-206977 RX | 2016-12-15 | 15 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
adthyza | unapproved drug other | 2023-02-23 |
adthyza thyroid | unapproved drug other | 2025-02-20 |
ermeza | New Drug Application | 2022-04-15 |
euthyrox | New Drug Application | 2024-10-24 |
levo-t | New Drug Application | 2024-07-31 |
levothroid | New Drug Application | 2012-03-02 |
levothyroxine | NDA authorized generic | 2014-09-24 |
levothyroxine sodium | ANDA | 2025-04-08 |
levoxyl | New Drug Application | 2020-12-15 |
np thyroid | unapproved drug other | 2021-05-11 |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Levothyroxine Sodium, Tirosint-Sol, Ibsa | |||
11241382 | 2039-09-17 | U-3757, U-3758 | |
10537538 | 2037-02-28 | DP | |
11096913 | 2037-02-28 | DP | |
Levothyroxine Sodium, Levolet, Genus Lifesciences | |||
10231931 | 2038-03-23 | DP | |
10406108 | 2038-03-23 | DP | |
Levothyroxine Sodium, Levothyroxine Sodium, Fresenius Kabi Usa | |||
9782376 | 2036-12-01 | DP | |
10398669 | 2036-12-01 | DP | |
11135190 | 2036-12-01 | DP | |
9006289 | 2032-10-03 | DP | |
9168238 | 2032-08-29 | DP | |
9168239 | 2032-08-29 | DP | |
Levothyroxine Sodium, Levothyroxine Sodium, Hikma | |||
11154498 | 2036-07-20 | DP | |
Levothyroxine Sodium, Ermeza, Mylan | |||
9345772 | 2035-02-27 | DP | |
Levothyroxine Sodium, Thyquidity, Azurity | |||
9050307 | 2031-08-06 | DP | |
Levothyroxine Sodium, Tirosint, Ibsa | |||
7691411 | 2024-03-14 | DP | |
7723390 | 2024-03-14 | DP |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 4 | — | — | — | — | 4 |
Drug common name | Levothyroxine |
INN | levothyroxine sodium |
Description | L-thyroxine is the L-enantiomer of thyroxine. It has a role as a thyroid hormone, an antithyroid drug, a human metabolite and a mouse metabolite. It is a thyroxine, an iodophenol, a 2-halophenol, a L-phenylalanine derivative and a non-proteinogenic L-alpha-amino acid. It is a conjugate acid of a L-thyroxine(1-). It is an enantiomer of a D-thyroxine. It is a tautomer of a L-thyroxine zwitterion. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O |
PDB | — |
CAS-ID | 51-48-9 |
RxCUI | — |
ChEMBL ID | CHEMBL1624 |
ChEBI ID | 18332 |
PubChem CID | 5819 |
DrugBank | DB00451 |
UNII ID | 054I36CPMN (ChemIDplus, GSRS) |